Mitomycin Accord

Mitomycin, the active ingredient in Mitomycin Accord, is an antineoplastic antibiotic presented as a sterile solution for intravenous and intravesical use. It is employed in the treatment of several solid tumours, including bladder, gastric, pancreatic, breast, and head‑and‑neck cancers, primarily in adult oncology patients.

GNH USA supplies Mitomycin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin Accord is an antineoplastic antibiotic used in the management of malignant tumours that rely on DNA synthesis pathways. - Bladder cancer: provides cytotoxic activity that can reduce tumour burden when administered intravesically. - Gastric cancer: contributes to tumour regression as part of combination chemotherapy regimens. - Pancreatic cancer: offers DNA cross‑linking effects that enhance overall response rates. - Breast cancer: used in selected protocols for advanced disease to inhibit cell proliferation. - Head and neck cancer: applied in combination therapy to improve local control.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring during or after infusion. - Myelosuppression: reduced white blood cells, red cells and platelets. - Hematuria: blood in urine, especially after intravesical administration. - Fatigue: generalized tiredness during treatment cycles.

Serious or Rare Side Effects: - Pulmonary fibrosis: progressive scarring of lung tissue. - Severe infection: opportunistic infections due to immunosuppression. - Renal toxicity: impaired kidney function, particularly with intravesical use.

Mitomycin requires careful monitoring and specific safety measures before, during and after administration. - Renal function: assess creatinine clearance prior to intravesical dosing. - Hepatic function: evaluate liver enzymes to adjust systemic exposure. - Hematologic monitoring: perform regular CBC to detect myelosuppression. - Pregnancy and lactation: avoid use; potential teratogenic risk is unknown. - Concomitant nephrotoxic agents: avoid or adjust dosing when used together. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mitomycin may interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - High‑dose cyclophosphamide: additive bone‑marrow suppression. - Nephrotoxic antibiotics (e.g., aminoglycosides): increased risk of renal injury. - Anticoagulants (warfarin, DOACs): heightened bleeding tendency.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate renal dysfunction. - CYP450 inducers (e.g., rifampin): could reduce mitomycin plasma levels.